key: cord-0942232-qd5p2ty1
authors: Stone, Nathan E.; Jaramillo, Sierra A.; Jones, Ashley N.; Vazquez, Adam J.; Martz, Madison; Versluis, Lora M.; Raniere, Marlee O.; Nunnally, Haley E.; Zarn, Katherine E.; Nottingham, Roxanne; Sahl, Jason W.; Wagner, David M.; Knudsen, Steen; Settles, Erik W.; Keim, Paul S.; French, Christopher T.
title: Stenoparib, an inhibitor of cellular poly (ADP-ribose) polymerase (PARP), blocks replication of the SARS-CoV-2 human coronavirus in vitro
date: 2020-11-16
journal: bioRxiv
DOI: 10.1101/2020.11.12.380394
sha: 4d5a82386d5d6eb6f4175a099853f80fbb3ca925
doc_id: 942232
cord_uid: qd5p2ty1

By late 2020, the coronavirus disease (COVID-19) pandemic, caused by SARS-CoV-2 has caused tens of millions of infections and over 1 million deaths worldwide. A protective vaccine and more effective therapeutics are urgently needed. We evaluated a new PARP inhibitor, stenoparib, which was recently advanced to Stage II clinical trials for treatment of ovarian cancer, for activity against human respiratory coronaviruses, including SARS-CoV-2, in vitro. Stenoparib exhibits dose-dependent suppression of SARS-CoV-2 multiplication and spread in Vero E6 monkey kidney and Calu-3 human lung adenocarcinoma cells. Stenoparib was also strongly inhibitory to the HCoV-NL63 human seasonal respiratory coronavirus. Compared to remdesivir, which inhibits viral replication downstream of cell entry, stenoparib impedes entry and post-entry processes as determined by time-of-addition (TOA) experiments. Moreover, a 10 μM dosage of stenoparib – below the approximated 25.5 μM half-maximally effective concentration (EC50), combined with 0.5 μM remdesivir suppressed coronavirus growth by more than 90%, indicating a potentially synergistic effect for this drug combination. Stenoparib as a standalone or as part of combinatorial therapy with remdesivir should be a valuable addition to the arsenal against COVID-19. Importance New therapeutics are urgently needed in the fight against COVID-19. Repurposing drugs that are either already approved for human use or are in advanced stages of the approval process can facilitate more rapid advances toward this goal. The PARP inhibitor stenoparib may be such a drug, as it is currently in Stage II clinical trials for the treatment of ovarian cancer and its safety and dosage in humans has already been established. Our results indicate that stenoparib possesses strong antiviral activity against SARS-CoV-2 and other coronaviruses in vitro. This activity appears to be based on multiple modes of action, where both pre-entry and post-entry viral replication processes are impeded. This may provide a therapeutic advantage over many current options that have a narrower target range. Moreover, our results suggest that stenoparib and remdesivir in combination may be especially potent against coronavirus infection.

The novel SARS-CoV-2 coronavirus emerged from Wuhan, China in late 2019, and rapidly spanned the globe in a devastating pandemic (1). The disease, COVID-19, compromises 50 the upper and lower respiratory systems and may affect all people (2). Although in many cases COVID-19 symptoms may be mild, some patients present with pulmonary distress leading to 52 severe lung damage, and treatment options are limited (1, 3-5). Mortality estimates range from 0.5% to more than 5% (6). According to the Johns Hopkins COVID Resource Center (7), as of 54

Nov. 10, 2020, over 10 million infections and more than 240,000 deaths have occurred due to COVID-19 in the USA alone, and the pandemic continues (8). A protective vaccine may become 56 available (1, 2), but unless sufficient immunity can be achieved in the population, COVID-19 has the potential to cause morbidity and mortality for years to come. Without a protective vaccine, 58 COVID-19 has largely been controlled through non-pharmaceutical measures such as quarantine, social isolation, and the use of personal protective equipment. Clearly, more efficacious 60 treatments are needed.

Individuals who contract COVID-19 are most commonly infected by person-to-person 62 transmission, where inhaled droplets containing infectious virions are seeded into the respiratory tract (1). The virions bind to respiratory epithelium via the affinity of the virus spike (S) complex 64 to the angiotensin converting enzyme 2 (ACE2) receptor (9) . A cellular serine protease TMPRSS2 plays a pivotal role in S protein priming (10) , which in turn facilitates fusion between 66 the viral and cellular plasma membranes and internalization of the virus-receptor complex by endocytosis. Subsequently, the virus is uncoated and releases its single-stranded RNA genome, 68 which is processed, translated, and replicated in the host cytosol. Copies of the viral genome are packaged into bilayer membrane envelopes, and these new infectious virions are exported from 70 the cell (11, 12) . The SARS-CoV-2 lifecycle is typical of other coronaviruses, including the highly virulent SARS-CoV, the cause of Severe Acquired Respiratory Syndrome (SARS) (9) . 72

Heel' that is broadly susceptible to therapeutic intervention. 74 Antiviral therapeutics impede interactions between the virus and the host cell. Potential targets include the virus binding to the cellular receptor, viral entry or virus-host membrane 76 fusion, viral transcription, translation, replication and export. (1). Stenoparib is an investigational, orally-available small molecule that inhibits poly (ADP-ribose) polymerase 78 (PARP), a key enzyme in DNA repair (13). Stenoparib is unique in that it has dual inhibitory activity against the PARP 1/2 and tankyrase 1/2 enzymes, which are important regulators of the 80 canonical Wnt/β-catenin checkpoint that is often dysregulated in metastatic breast cancer (14) .

Until August 2020, stenoparib was known as "2X-121" and previously as "E7449". Recently, 82 another PARP inhibitor mefuparib (CVL218) was shown to inhibit SARS-CoV-2 in vitro.

CVL218 suppressed SARS-CoV-2 infection in Vero E6 African Green Monkey cells (15) . As 84 implied by molecular modeling studies, CVL218 and other PARP inhibitors may block viral replication by interfering the viral nucleocapsid (N) protein binding to an RNA template (15 Altogether, reproposing can produce more rapid and efficient returns (16, 18) . Stenoparib is currently in Phase II clinical trials for the treatment of ovarian cancer (14) . Based on the recent 96 promising results of the PARP inhibitor CVL218 against SARS-CoV-2 in vitro (15), we evaluated the activity of stenoparib against SARS-CoV-2, with an eye toward its use as a 98 treatment for COVID-19.

Stenoparib inhibits the replication of SARS-CoV-2 in Vero E6 cells. Based on the reported antiviral activity of other PARP inhibitors on SARS-CoV-2 in vitro (15) we aimed to 104 determine whether stenoparib possessed a similar activity against the virus. Stenoparib was prepared as a solution in dimethylsulfoxide (DMSO) and used to treat Vero E6 cells infected 106 with SARS-CoV-2 (USA-WA1/2020). Vero E6 is a common cell platform for propagating coronaviruses, including SARS-CoV-2 and SARS-CoV (19, 20) . At 48 hours (h) after infection, 108

RNA was isolated from cell supernatants, and viral copy number was estimated by reversetranscription quantitative real-time polymerase chain reaction (RT-qPCR). Viral RNA 110 measurements were compared to untreated cell controls, and to infected cells treated with a cocktail of camostat mesylate and E64d ('C/E'), which are protease inhibitors that impede 112 processing of the virus spike protein and interfere with its entry into the cell (10, 21) . In parallel, we assessed potential toxic effects of stenoparib using the lactate dehydrogenase release assay, 114 which indicates cytotoxicity due to cell lysis. As shown in Fig. 1 displayed marked cytotoxicity to Vero E6 cells ( Fig. 2A) , which limited our capacity to comprehensively test the activity of the drug. We used a stenoparib response software predictor 122 to pre-assess the susceptibility of human tumor cells based on the quantitative activity of 414 genes (22) . When applied to human cell lines used with SARS-CoV-2 (23), the algorithm 124 predicted that LLC-MK2 cells would be less sensitive to stenoparib toxicity than Vero E6 cells.

The cell line Calu-3, originally isolated from the pleural effusion of a patient with lung 126 adenocarcinoma (24) , was predicted to be even more resistant than LLC-MK2. We verified this prediction for Calu-3 cells using stenoparib concentrations up to 60 µM, and exposure for up to 128 120 h, with no elevation in cytotoxicity over baseline conditions (t=8.237, P=0.0144) (Fig. 2B ).

Calu-3 lung epithelial cells as a platform for SARS-CoV-2. Since Calu-3 cells were 130 more resistant to the toxic effects of stenoparib than Vero E6 cells, we utilized Calu-3 cells to test the effectiveness of higher doses than were previously achievable with Vero E6. The viral 132 plaque assay comprehensively assesses inhibitors on the viral intracellular lifecycle, from virus entry, to multiplication, and cell to cell spread. Plaques result from cell damage and death 134 following infection, appearing as empty regions or "dead zones" in the cell monolayer (25) .

Fresh media containing 2% FBS, with or without stenoparib or C/E control inhibitors, was 136 applied to confluent monolayers of Calu-3 cells, which were then infected with SARS-CoV-2 for 1 h. At this time the infection media was removed, and the cells were overlaid with a semisolid 138 matrix consisting of cell growth medium in 1.2% low melting temperature agarose, with or without stenoparib or control inhibitors. At 120 h post infection, cells were fixed with 140 paraformaldehyde, stained with crystal violet, and the number of plaques were visually counted. replication, achieving a 69.3% and 95.8% reduction of plaquing efficiency and viral copy number with 30 µM stenoparib, measured by plaque assay and RT-qPCR, respectively, 168 compared to untreated controls (t=7.982 and 12.82, P=0.0002 for both) (Fig. 4A and Fig. 4B ).

may target one or several intracellular growth stages, including virus entry (camostat mesylate, hydroxychloroquine), endosomal processing (hydroxychloroquine, rapamycin), translation and 172 RNA processing (lopinavir), and transcription and replication (remdesivir) (1, 11, 30) . By altering the time of addition (TOA) and duration of treatment in vitro, we can discern whether a 174 drug affects virus entry, intracellular growth, or both. TOA experiments were conducted using the viral plaque assay with NL63 as a surrogate for SARS-CoV-2. RT-qPCR was performed in 176 parallel to measure viral loads. We used remdesivir as a reference inhibitor, since its mechanism, target and dosage range are known (31). Experiments to determine the lifecycle stages affected 178 by stenoparib were performed as follows: a) to ascertain the effect on virus entry, cells were Bioquest, Inc, 26 Oct. 2020, https://www.aatbio.com/tools/ec50-calculator). We hypothesized that a combination of stenoparib and remdesivir would be more potent than the individual 228 compounds. To test this, we combined a range of doses of stenoparib with 0.5 µM remdesivir and tested these for activity against NL63. 230

As shown in Fig. 6 , complete inhibition of NL63 plaque formation was achieved with 60 µM stenoparib, in line with our earlier results with SARS-CoV-2 and Calu-3 cells (Fig. 3) . 232

Complete inhibition was also achieved with 1.0 µM remdesivir. However, a combination of 10 µM stenoparib and 0.5 µM remdesivir was more effective than either compound alone at these 234 doses, achieving 90.7% inhibition for the combination, vs. 18.5% inhibition for 10 µM stenoparib, and 65.6% for 0.5 µM remdesivir, suggesting at least additive effects when the drugs 236 are combined. Notably, the stenoparib dose (10 µM) used in the combination is far below the compound's EC50 of 25.5 µM. Altogether, these results support investigating the use of 238 stenoparib and remdesivir as a combinatorial therapy for SARS-family coronavirus infections.

Prior to the emergence of COVID-19, attempts to identify inhibitors of coronavirus were 242 mainly focused on SARS-and MERS-CoVs. The recent efforts to develop COVID-19 therapeutics spans the gamut from new drug discovery to repurposing existing drugs. There are 244 some excellent reviews on the subject (17, 41) . Here, we focus on the compound stenoparib, formerly known as 2X-121, an inhibitor of the cellular enzyme PARP-1/2. Stenoparib is thought 246 to inhibit SARS-CoV-2 by multiple mechanisms, predominately by inhibiting of ADPribosylation of proteins required for virus replication and assembly (42) . ADP-ribosylation is a 248 conserved, post-translational modification that is key for proper formation of the coronavirus nucleocapsid, and inhibition can negatively affect packaging of the viral genome and virion 250 stability. Specific targets of ADP-ribosylation include viral nsp3 protein, which is essential for virulence and a component of the replication/transcription complex (RTC) (43, 44) . Moreover, 252 PARP inhibitors may exert additional protective effects at the host and cellular levels by reducing depletion of NAD+ and ATP that leads to cell necrosis (40) , as well as decreasing the 254 pro-inflammatory NF-kB-triggered cytokine storm that can damage host organs (45). It has also been suggested that PARP inhibitors enhance the degradation of the host type I interferon 256 receptor (IFN-1R), which would also have a modulatory effect on the host inflammatory response (46) . 258

In this study, inhibition of SARS-family coronaviruses by stenoparib in vitro is likely due to interference with multiple stages of the virus lifecycle. Consistent with its predicted 260 mechanism, stenoparib is effective when introduced post-infection. Additionally, we noted an association between stenoparib treatment and decreased virus counts soon after infection. This 262 may reflect activity against multiple targets, including those involved in promoting virus entry.

Stenoparib interference with the activity of tankyrase and Wnt/b-catenin signaling can 264 downregulate expression of the ACE2 receptor, leading to a decrease in the number of viruses that can enter the cell, which is consistent with effects on virus entry and with our observations. 266

In contrast, inhibition by remdesivir was predominately on post-entry events -its effect on virus entry was minimal at best, which is in line with its specific MOA of targeting the virus 268 replication machinery. Overall, our observations imply multiple mechanisms for stenoparib, including impeding of viral entry and intracellular growth via modifications of multiple viral and 270 host proteins.

Other human coronaviruses that utilize ACE2 for binding and entry may be suitable as 272 surrogate platforms for the study of SARS-CoV-2 in vitro, so long as they can be propagated in the laboratory and are able to elicit cellular infection phenotypes that can be quantitatively 274 measured. We show that the human seasonal coronavirus NL63, which can cause a cold-like illness in humans (26), is such an example. Like SARS-CoV-2 and SARS-CoV, NL63 is 276 internalized following the binding of viral S-complex proteins to the ACE2 receptor (28, 47-49).

According to our observations, NL63 is susceptible to inhibition by compounds that affect 278 SARS-CoV-2, including remdesivir, the protease inhibitors camostat mesylate and E64d, and stenoparib, the subject of this study. 280

In light of the in vitro cytotoxic effects of stenoparib, we were unable to test it in Vero E6 cells against SARS-CoV-2 at doses exceeding 30 µM. Stenoparib was developed as a cytotoxic 282 drug for cancer treatment (14) , so it is not surprising that it showed dose-dependent cytotoxicity against rapidly-dividing Vero E6 cells. PARP inhibitors typically express their lethality after 284 several replication cycles (50). The susceptibility of Vero E6 cells to stenoparib toxicity may be linked to its fast-growing phenotype, since two replication cycles can be achieved in as little as 286 48 h. Although LLC-MK2 cells, which are utilized for propagation and testing of NL63 are substantially more resistant to stenoparib, their susceptibility to SARS-CoV-2 infection is 288 suboptimal. We were thus presented with a conundrum in how to test high doses of stenoparib against SARS-CoV-2 to assess its maximum activity. This was addressed through the use of the 290 Calu-3 human lung carcinoma cell line to model SARS-CoV-2 infections. Our results confirm the suitability of Calu-3 as a host for SARS-CoV-2 and its high degree of resistance to stenoparib 292 toxicity. This characteristic of Calu-3 cells was predicted in silico using a method previously employed on clinical tumor biopsies (22) , and experimentally validated in this study. Infection of 294

Calu-3 monolayers with SARS-CoV-2 formed large, clearly visible plaques, and in this regard, the performance of Calu-3 surpassed Vero E6. A notable characteristic of Calu-3 is its slow 296 growth properties, which may coincide with a general degree of resistance to compounds that target essential cellular pathways and are toxic to more rapidly dividing cells. 298

A promising drug to emerge from COVID therapeutic trials is the nucleoside analog remdesivir, which shows activity against phylogenetically diverse viruses including Ebola, 300

Nipah, respiratory syncytial virus (RSV), and coronaviruses such as SARS-and MERS-CoV (51), SARS-CoV-2 (31) and, as reported here, the seasonal human HCoV-NL63. Reviews on the 302 MOA of remdesivir have been published (17, 41, 51). After entering the cell, remdesivir is triple phosphorylated to form remdesivir-triphosphate, and this structure is thought to inhibit RNA 304 polymerase, resulting in chain termination. While the precise molecular mechanism is not clear (51), the EC50 of remdesivir has been reported to be 0.77 µM for SARS-CoV-2 (31), which is in 306 line with our measurement of 0.54 µM for SARS-CoV-2, and comparable to our experimentallydetermined EC50 of 0.46 µM against NL63. 308

While remdesivir inhibits the viral replicon, our data support multiple targets for stenoparib. Moreover, stenoparib and remdesivir may be a potent combination at inhibiting 310 SARS-family coronaviruses inside cells. A mixture of 10 µM stenoparib and 0.5 µM remdesivir was more successful at inhibiting the NL63 virus than either compound alone at these doses. Plaque assays. 6-well plates (CLS3516, Millipore Sigma) were seeded with ~3.0x10^5 cells/well and incubated for 48-72 h at 37°C in 5% CO2 until 80-90% confluency was reached. 334

Calu-3 cells were incubated for >10 days to achieve 80-90% confluency. Prior to infection the media was replaced with fresh media containing 2.0% FBS with varying concentrations of 336 stenoparib as appropriate for each experiment (see results) and infected with coronavirus (SARS-CoV-2 or NL63) at an MOI of 0.013 for SARs-CoV-2 and 0.003 for NL63. Media was then 338 replaced with a 1 X Dulbecco's MEM (DMEM -Millipore Sigma) / 1.2% low-melting agarose (Bio-Rad) overlay containing the appropriate drug concentration for each experiment. This was 340 allowed to solidify at room temperature for 15 minutes, and incubated for 120 h at 37°C in a 5% CO2 atmosphere. A cocktail of the protease inhibitors camostat mesylate and E64d (C/E) was a 342 control for all experiments (21) . SARS-CoV-2 manipulations were conducted in a BSL-3 facility. 2.0 ml of 4% paraformaldehyde was added to each overlay for 30 minutes, followed by 344 staining with 1.0% crystal violet, removal of the overlay, and a triple rinse with PBS. Plaque forming units (pfu) were counted, averaged, and normalized to the untreated control group. Each 346 run contained three biological replicates and was conducted a minimum of two times. Standard deviation was calculated using the variation of averaged counts among all runs. Values were 348 plotted using GraphPad Prism version 8.0.0 for Windows (GraphPad Software) and annotated using Adobe Illustrator (Adobe Systems Incorporated). Statistical significance was determined 350 using a parametric unpaired t-test in GraphPad Prism version 8.0.0.

Sigma) were seeded with ~1.0x10^5 cells/well and incubated until 80-90% confluency was reached. Growth media was replaced and infected with coronavirus (SARS-CoV-2 or NL63) at 354 an MOI of 0.04 for SARs-CoV-2 and 0.01 for NL63 for up to 120 h at 37°C in 5% CO2 atmosphere. C/E was used as a control inhibitor for all experiments. Each run contained two 356 biological replicates and was conducted three times. 400 µL of supernatant was harvested at 48 h for SARS-CoV-2, 120 h for NL63. RNA was extracted using Invitrogen Pure-Link RNA kits 358 (Thermo Fisher) according to their recommendations.

assays were designed for the SARS-CoV-2 or the NL63 coronaviruses. For NL63, the reference genome (NC_005831) was divided into 200 nucleotide fragments, which were aligned against a 362 set of 2,771 coronavirus genomes with BLAT v36.2 (52) in conjunction with LS-BSR v1.2.2 (53). Regions were identified that had a BLAST score ratio (BSR) (54) value ≥0.8 in 60 NL63 364 genomes, and a BSR value <0.4 in all other coronavirus genomes. A total of 10 fragments were highly specific to all NL63 genomes. Primers and probes were identified using Primer3 v2.3.6 366 (55) . A similar process was conducted for SARS-CoV-2 assay design, except the GCF_009858895.2 reference genome was used. A total of 4 fragments were unique to 64 distinct 368 SARS-CoV-2 genomes. A probe was designed targeting the spike (S) protein furin cleavage site with Primer3. 370

The SARS-CoV-2 qPCR amplified a 125 bp region of the S protein using forward primer values represent the average of the two independent experiments (reported in Fig. 2A 

Plaque forming efficiency using SARS-CoV-2. Values are normalized as a percentage of inhibition compared to infected, but untreated cells. Plaques were counted 120 h after infection, 638

replicates from each run were averaged, and assays were performed three times. Error bars are based on the standard deviation across all runs. B) RT-qPCR was performed on viral RNA 640 collected from cell culture supernatants at 48 h post infection and replicate values within each run were averaged; a total of three runs were performed. Error bars are based on averaged 642 standard deviations within runs. Cytotoxicity against Calu-3 cells was determined at 48 and 120 h, as appropriate, using the Promega™ CytoTox 96™ assay kit, and values represent the average 644 of the two independent experiments (reported in Fig. 2B ).

Plaquing efficiency values are normalized as a percentage of inhibition compared to infected, but 650 untreated cells. Plaques were counted 120 h after infection, and assays were performed three times. Error bars are based on the standard deviation across all runs. B) RT-qPCR was performed 652 on viral RNA collected from cell culture media at 120 h post infection. Biological replicates from each run were averaged, and three independent runs were performed. Error bars were based 654 on averaged standard deviations within runs. Cytotoxicity against LLC-MK2 cells was determined at 120 h using the Promega™ CytoTox 96™ assay kit, and values represent the 656 average of the three independent experiments. unit counts from each run were averaged. Error bars are based on standard deviation among runs. Brackets indicate the t-test comparison and P-value for the "Entry" group. No significant 666 difference was observed between stenoparib and remdesivir under any treatment. N/D indicates that no plaques were detected in these treatment groups. B) RT-qPCR was performed on viral 668

RNA collected from cell culture media at 120 h post infection and replicate values within each run were averaged; a total of three runs were performed. Error bars were based on averaged 670 standard deviations within runs. Brackets indicate the t-test comparison and P-value for the "Entry" group. Significant differences were observed between stenoparib and remdesivir under 672 all treatments.

Plaque assays were performed a minimum of two times and replicate values from each run were 676 averaged. Plaquing efficiency values are normalized as a percentage of inhibition compared to infected, but untreated cells. Three data sets are plotted to illustrate the treatment of NL63 with 678 1) stenoparib and 2) remdesivir as monotherapies and as a 3) combination therapy, whereby increasing concentrations of stenoparib are combined with 0.5 µM remdesivir; the EC50 was 680 computationally approximated at 0.46 µM. The stenoparib monotherapy data is the same as previously reported (Fig. 4A) . The synergistic activity threshold is defined as the sum of the 682 mean values of 10 µM stenoparib and 0.5 µM remdesivir as monotherapies, while the grey highlighted area represents the minimum and maximum possible additive activity values based 684 on the range of error for those same concentrations observed during these experiments. stenoparib. Plaques are identified as empty regions or "dead zones" in the cellular monolayer and are expressed as plaque forming units (PFUs) per well. Plaques were manually counted and 700 averaged among experimental replicates. This score is normalized as a percentage of untreated, but infected cells. In this representative image of the SARS-CoV-2/Calu-3 experiment, plaques 702 are dark scars on the cellular monolayer. Controls were 1) uninfected cells (Cell Ctl), 2) untreated, but infected cells (0 µM), and 3) a camostat mesylate and E64d (C/E) inhibitor control 704 (Inhibitor Ctl). Treatment with stenoparib at 10 µM and 30 µM led to a marked reduction in plaquing efficiency, whereas 60 µM resulted in near complete inhibition. 706

Characteristics of SARS-CoV-2 and COVID-19

Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China Summary of a

Cases From the Chinese Center for Disease Control and Prevention

Association between age and clinical characteristics and outcomes of COVID-19

Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease

Clinical Characteristics of Coronavirus Disease 2019 in China

An interactive web-based dashboard to track COVID-19 in real time

Modeling COVID-19 scenarios for the United States

SARS-CoV-2 468 and Coronavirus Disease 2019: What We Know So Far

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and

Drugs targeting various stages of the SARS-474

CoV-2 life cycle: Exploring promising drugs for the treatment of Covid-19

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): An overview of viral structure and host response

PARP inhibitors: review of mechanisms of action and BRCA1/2 mutation targeting

E7449: A dual inhibitor of PARP1/2 and tankyrase1/2 inhibits growth of DNA repair deficient tumors and 484 antagonizes Wnt signaling

A data-driven drug repositioning framework discovered a potential therapeutic agent targeting COVID-19

Drug 492 repurposing: progress, challenges and recommendations

Repurposing Drugs, Ongoing Vaccine, and New

Therapeutic Development Initiatives Against COVID-19

Network-based drug 498 repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2

The life cycle of SARS coronavirus in Vero E6 cells

SARScoronavirus-2 replication in Vero E6 cells: replication kinetics, rapid adaptation and 504 cytopathology

Targeting the entry step of SARS-CoV-2: a promising 506 therapeutic approach

Firstin-human study of the PARP/tankyrase inhibitor E7449 in patients with advanced solid 510 tumours and evaluation of a novel drug-response predictor

Comparative tropism, replication kinetics, and cell damage profiling of SARS-CoV-2 and SARS-CoV with implications for clinical manifestations, transmissibility, and laboratory 516 studies of COVID-19: an observational study

One hundred and twenty-seven cultured human tumor 518 cell lines producing tumors in nude mice

Viral concentration determination through plaque assays: 520 using traditional and novel overlay systems

Differential downregulation of ACE2 by the spike proteins of severe acute respiratory syndrome 526 coronavirus and human coronavirus NL63

The S proteins of human coronavirus NL63 and severe acute respiratory syndrome coronavirus bind overlapping regions of ACE2

Identification of cell lines permissive for human coronavirus NL63

Targeting T-cell 534 senescence and cytokine storm with rapamycin to prevent severe progression in COVID-19

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus 538 (2019-nCoV) in vitro

Structure-based virtual screening and experimental validation of the discovery of inhibitors targeted towards the human coronavirus nucleocapsid protein

Antitumour effect of combination treatment with Sabarubicin (MEN 10755) and cis-platin (DDP) in human lung tumour xenograft

Dutrebis (lamivudine and raltegravir) for use in combination 548 with other antiretroviral products for the treatment of HIV-1 infection

Best drug treatment for multidrugresistant and extensively drug-resistant tuberculosis

CISNE: An accurate description of dose-effect and synergism in combination therapies

Synergism between streptomycin and penicillin

Phenotypic landscape of a bacterial cell

In vitro and in vivo synergism between amoxicillin and clavulanic acid against ampicillin-resistant Haemophilus influenzae type b

The molecular story of COVID-19; NAD+ depletion addresses all questions in this infection

Recent discovery and 568 development of inhibitors targeting coronaviruses

The coronavirus nucleocapsid 570 protein is ADP-ribosylated

Nsp3 of coronaviruses: Structures and functions of a 572 large multi-domain protein

The nsp3 macrodomain promotes virulence in mice with coronavirus-induced encephalitis

Role of poly (ADP) ribose polymerase-1 inhibition by nicotinamide as a possible additive treatment to modulate host immune response and prevention of 578 cytokine storm in COVID-19

The cytokine storm in 580 COVID-19: An overview of the involvement of the chemokine/chemokine-receptor system

Human angiotensin-converting enzyme 2 (ACE2) is a receptor for human respiratory 584 coronavirus NL63

Interaction between the spike protein of human coronavirus NL63 and its cellular receptor ACE2

Identification of residues in the receptor-binding domain (RBD) of the spike protein of human coronavirus NL63 that are critical for the RBD-ACE2 receptor interaction

Systematic identification of genomic markers of drug sensitivity in cancer cells

Probable Molecular Mechanism of Remdesivir for the Treatment of COVID-19: Need to 602 Know More

BLAT--the BLAST-like alignment tool

The large-scale blast score ratio (LS-BSR) pipeline: a method to rapidly compare genetic content between bacterial genomes

Visualization of comparative genomic analyses by 608 BLAST score ratio

Primer3 on the WWW for general users and for biologist 610 programmers